Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

National Defense November 2005 Margaret Davidson	Biodefense Experts: Vaccines `At a Crossroads' Many of the companies seeking government funds for biodefense work are small firms with no experience in bringing a drug to market. And they face a significant challenge.
National Defense June 2007 Breanne Wagner	Agencies Scramble to Create Vaccine Market Defense and Homeland Security are pursuing disparate vaccination programs to combat different needs for military and civilian populations.
Bio-IT World September 16, 2004 Zachary Zimmerman	The Dark Side of Project BioShield Despite the uncertainties, an estimated 100 biopharma companies are developing anti-terror technologies. But they should examine both sides of Project BioShield before considering product development.
National Defense June 2011 Eric Beidel	Industry, Academia Race to Create Drugs Against Biological Warfare On the heels of anthrax comes a string of deadly agents that scientists also fear can be used as weapons and spread with ease.
Salon.com March 8, 2001 Amy Standen	Ready for some lockjaw? There's no profit in the tetanus vaccine business, so a rare and hideous disease may soon strike more Americans...
Pharmaceutical Executive July 3, 2007 Jill Wechsler	Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries.
The Motley Fool December 13, 2011 Frank Vinluan	N.C. Novartis Site Is First Cell-Based Flu Vaccine Facility in the Country A Novartis' vaccine facility in North Carolina today became the first facility authorized by the FDA for emergency use during a pandemic.
BusinessWeek January 9, 2006 Carol Matlack	Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine.
National Defense March 2005 Sandra I. Erwin	Pentagon Redirects Priorities In Chemical-Biological Defense The Pentagon will broaden the scope of its chemical and biological defense programs, in an effort to prepare for future domestic emergencies, officials say.
BusinessWeek April 26, 2004 Kerry Capell	Vaccinating The World's Poor GlaxoSmithKline Biologicals is betting it can combat Third World scourges -- and still make money.
Pharmaceutical Executive May 1, 2006 Pasternak et al.	Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity?
The Motley Fool December 13, 2007 Brian Orelli	Merck's Vaccination Woes Merck announces it is recalling 1.2 million doses of a vaccine that immunizes children against Hib, which causes meningitis, pneumonia, and other serious infections.
HBS Working Knowledge March 1, 2004 Martha Lagace	Injecting New Life into the Vaccine Industry Vaccines for preventable diseases save millions of lives every year, yet as an industry, the vaccine business suffers a host of ailments, the CEO of Merck & Co. contends.
Chemistry World March 17, 2011 Hepeng Jia	International recognition helps Chinese vaccine industry Vaccines made in China will now be supplied through United Nations agencies to developing countries, after recognition from the World Health Organisation that China's State Food and Drug Administration has complied with international standards for vaccine regulation.
BusinessWeek July 25, 2005 Catherine Arnst	O.K., Roll Up Your Sleeve New vaccines are arriving but the economics are still a challenge.
Pharmaceutical Executive June 1, 2005 Seth Berkley	Backpage: Partnering for Vaccine Victories Public-private partnerships can help engage industry in AIDS vaccine research. Pharma and biotechnology companies should respond with the expertise that only they can offer.
HBS Working Knowledge February 28, 2005 Cynthia Churchwell	Funding R&D for Neglected Diseases Research on vaccines for diseases that primarily affect low-income countries remains minimal---the risks are too high for developers. The book Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases suggests a solution.
Bio-IT World Dec 2005/Jan 2006 Salvatore Salamone	Gates, Clinton Address Global Health Summit The conference brought together leaders in business, government, medicine, public philanthropic groups, and the arts to address and develop solutions to the world's heath crises.
The Motley Fool June 26, 2008 Brian Lawler	Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay.
BusinessWeek October 24, 2005 John Carey	New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work?
The Motley Fool May 22, 2007 Mike Havrilla	An Emergent Opportunity The vaccine developer guided for revenue growth of 10% to 15% for this year. Emergent also has a strong balance sheet, with more than $67 million in cash and investments. Investors, take note.
Managed Care October 2000 Kevin A. Wilson	Public Policy Largely Ignores Adult Immunization Needs Although four fifths of the nation's children are fully immunized, tens of thousands of adults die each year from diseases preventable by vaccination...
The Motley Fool October 6, 2004 Rich Duprey	Chiron Sneezes, Investors Catch Cold British authorities shut down the pharmaceutical's only U.S. flu vaccine manufacturing facility. This may in fact be an opportunity to scoop up a beleaguered stock at fire sale prices.
The Motley Fool May 28, 2009 Brian Orelli	How to Make a Stockpile in Your Portfolio The swine flu has turned out to be a relative dud, hasn't it? It hasn't done much but create a buying opportunity for those who didn't panic. Where should you look to profit from it now?
The Motley Fool May 27, 2005 Rich Duprey	Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm.
Fast Company January 2002 George Anders	The Real Biohazards We do face bioterrorism -- but the three threats we face aren't anthrax, smallpox, and pneumonic plague...
Salon.com October 26, 2001 Chris Colin	Is there an anthrax doctor in the house? Scoops are few and desperation is catching at the annual conference of the Infectious Diseases Society of America...
The Motley Fool December 30, 2008 Brian Orelli	A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus.
The Motley Fool January 26, 2005 Rich Duprey	Chiron's Earnings Ills Flu vaccine manufacturer expected to report significantly lower profits.
Salon.com October 27, 2000 Arthur Allen	A cure worse than the disease? Fearing sickness and debilitation, startling numbers of American troops are refusing to take mandatory anthrax vaccinations...
The Motley Fool September 16, 2009 Brian Orelli	Here Come the Swine Flu Vaccines Drugmakers moved one step closer to getting swine flu vaccines into your arm with approvals by the Food and Drug Administration.
BusinessWeek October 25, 2004 John Carey	A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked.
Pharmaceutical Executive February 1, 2009 Joanna Breitstein	Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most.
National Defense August 2005 Joe Pappalardo	Pentagon Spurs its Biological And Chemical Defense Programs The Pentagon is trying to buttress the military's defensive posture against biological and chemical weapons by focusing on the development of advanced vaccines and improved therapeutics. A surge in money is fueling this effort.
Entrepreneur May 2010 Jason Daley	Big Shot Meet the entrepreneurial nurse who found opportunity on the end of a needle.
The Motley Fool October 29, 2004 Selena Maranjian	Flu Shots for the Elite The flu shot shortage offers some food for thought for investors. Here are some statistics showing the establishment has some problems with the priorities when it comes to the flu.
Scientific American November 2008 John Dudley Miller	Postal Anthrax Aftermath: Has Biodefense Spending Made Us Safer? The Anthrax attacks in 2001 led to a massive increase in biodefense funding, which critics claim has done more harm than good
Pharmaceutical Executive December 1, 2005 Anthony Tao	The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late?
IndustryWeek August 1, 2003 Traci Purdum	Locations -- Out With The Old, In With The New Aventis Pasteur Inc. bids farewell to an old Pennsylvania facility to make room for bigger and better.
The Motley Fool September 7, 2005 Stephen D. Simpson	Smashing Good Deal, Eh? Glaxo's purchase of Canadian ID Biomedical will seriously augment its vaccine capabilities. Investors, take note.
American Family Physician December 1, 2002 Sanford R. Kimmel	Vaccine Adverse Events: Separating Myth from Reality Vaccines have turned many childhood diseases into distant memories in industrialized countries. However, questions have been raised about the safety of some vaccines because of rare but serious adverse effects that have been attributed to them.
Scientific American July 2006 JR Minkel	Dangling a Carrot for Vaccines Drug companies do not see much of a market in treating diseases of developing nations. Michael Kremer hopes to change that with a plan that taps the profit motive.
The Motley Fool August 21, 2009 Brian Orelli	Forget Swine Flu: The Big Money Is Here Vaccines are pharma's, and possibly investors', best friend.
Chemistry World September 16, 2015 Patrick Walter	A shot in the arm It's heartening news that an Ebola vaccine has delivered outstanding results and that a malaria one shows early promise.
The Motley Fool October 26, 2011 Chris Baines	Why Getting A Flu Shot Is Critical Vaccines save the lives of millions. By getting a flu shot, you're also aiding future vaccine research conducted by major pharmaceutical companies.
Chemistry World February 2006	Editorial: Fighting Avian Flu Participants at a world avian flu conference in Beijing committed to increasing cooperation on global vaccine and anti-viral research and development.
The Motley Fool September 2, 2005 Rich Duprey	Will Flu Vaccine Catch Cold? The CDC says we may have as many as 97 million doses this year, but that's a best-case scenario. This year again, it's Chiron causing the uncertainty.
National Defense September 2004 Joe Pappalardo	Security Beat Vaccine Stockpiles Now Required by Law... Commission: Military Had No Warning During 9/11... Simulated Agent Mimics Bio-Terror Weapons... Cyber-security Hampered by Lack of Attention...
Salon.com October 9, 2001 Suzy Hansen	Plague fears A bioterrorism expert talks about the wicked ways of anthrax and the even deadlier potential scourge of smallpox...
Pharmaceutical Executive December 1, 2005 Sarah Houlton	Global Report: Wanted: Attention Bird flu is number one on the media's agenda. But other diseases need better immunization, too. WHO estimates that in 2002, 2.1 million people died from diseases that could have been prevented by vaccines that WHO currently recommends.